Fibrotic Interstitial Lung Disease Clinical Trial
— HIIT in fILDOfficial title:
High Intensity Interval Training in Fibrotic Interstitial Lung Disease: a Randomized Controlled Trial
The fibrotic interstitial lung diseases (fILD) is a group of debilitating chronic lung conditions that are characterised by scarring of lung tissue, dyspnoea on exertion and significant physical impairment. Exercise training is recommended for people with fILD in improving breathlessness and exercise tolerance. However, despite the best efforts of patients and clinicians, many of those who participate are not attaining its benefits. The current exercise training strategies of moderate intensity continuous training may not be well suited to fILD. High intensity interval training (HIIT), short bouts of high-intensity exercise regularly interspersed with periods of rest or light exercise may be an alternate exercise training option for people with fILD. The study will determine to whether HIIT is better than the current method of continuous exercise training at moderate intensity in improving exercise tolerance, breathlessness and quality of life in people with fILD. A randomised controlled, assessor blinded trial will be conducted. A total 130 people with fILD will be randomly assigned to moderate intensity continuous training or HIIT. If this trial demonstrates that HIIT is effective, it will provide an exercise training strategy that can readily be implemented in practice that will maximise the outcomes of exercise training for people with fILD.
Status | Recruiting |
Enrollment | 130 |
Est. completion date | October 2024 |
Est. primary completion date | April 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis of fibrotic interstitial lung disease (fILD) - Able to read and speak English Exclusion Criteria: - Resting oxygen saturation (SpO2) is < 85% - Severe pulmonary hypertension (WHO class IV) - Attendance at Pulmonary rehabilitation (PR) within last 12 months - Comorbidities which preclude exercise training - History of syncope on exertion - Significant cognitive impairment - Anticipated transplant or death within the duration of the study period |
Country | Name | City | State |
---|---|---|---|
Australia | Prince Charles Hospital | Brisbane | Queensland |
Australia | Austin Health | Heidelberg | Victoria |
Australia | Alfred Health | Melbourne | Victoria |
Australia | Royal Prince Alfred Hospital | Sydney | New South Wales |
Lead Sponsor | Collaborator |
---|---|
Monash University |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in endurance time | Endurance time measured during constant work rate test (CWRT) at 75% of the peak work rate achieved on a baseline cardiopulmonary exercise test (CPET). | Baseline, nine weeks and 6 months following intervention | |
Secondary | Change in dyspnea measured using the Dyspnea-12 questionnaire | Dyspnea-12 is a uni-dimensional 12-item questionnaire divided in 2 domains: physical items (1 to 7) and affective items (8-12). Each item evaluate breathing experience and can be scored as: None (0), Mild (1), Moderate (2) or Severe (3). Results of this questionnaire will be reported as total score that can range from 0 to 36 and separate scores that can range from 0 to 21 for physical component and 0 to 15 for affective component. Higher scores indicate worse dyspnea. | Baseline, nine weeks and 6 months following intervention | |
Secondary | Changes in fatigue evaluated by the Fatigue Severity Scale | Fatigue Severity Scale (FSS), a self reported rating scale including 9 items to measure how fatigue affects motivation, exercise, physical functioning, carrying out duties and how fatigue interferes with work, family, or social life. Each item is scored on a 7 point scale in which 1 = strongly disagree and 7= strongly agree. Total score range from 9 to 63. Higher scores indicate greater fatigue severity. | Baseline, nine weeks and 6 months following intervention | |
Secondary | Change in health related quality of life using the St George's Respiratory Questionnaire idiopathic pulmonary fibrosis specific version (SGRQ-I) | The SGRQ-I is a disease specific HRQoL measure with similar psychometric properties to the original SGRQ that is designed to be more relevant in patients with IPF. The questionnaire is divided in 3 domains: Symptoms (frequency and severity), Activity (activities that cause or are limited by breathlessness) and Impact (social functioning and psychological disturbances resulting from airways disease). Values of each domain as well as the total score value will be reported. Each item is weighted based on empirical data. Total score and scores in each domain can range from 0 to 100. Higher scores indicate more limitations in quality of life. | Baseline, nine weeks and 6 months following intervention | |
Secondary | Change in health related quality of life using the chronic respiratory disease questionnaire (CRQ) | The CRQ consists of 20 items across 4 domains: Dyspnea (activities that cause breathlessness and are performed frequently), fatigue, emotional function and mastery ( the patient's feeling of control over their disease). Each domain includes four to seven items, and each item is scored on a 7-point Likert score. Total scores for each domain range from 4-35. Values of each domain will be reported. Lower scores indicate more limitations in quality of life. | Baseline, nine weeks and 6 months following intervention | |
Secondary | Change in anxiety and depression measured by the Hospital Anxiety and Depression Scale | Hospital Anxiety and Depression Scale (HADS), a scale with 14 items divided into two domains : anxiety symptoms (7 items) and depression symptoms (7 items). Each item can be scored from 0 to 3. Scores from each domain can vary from 0 to 21 and are stratified as follows: 0-7 (indicates absence of anxiety/depression symptoms); 8-10 ( presence of symptoms of anxiety and depression in moderate degree - borderline); 11 or more (significant number of anxiety/depression symptoms - confirmed cases). Score of each domain as well as number of confirmed cases will be reported. | Baseline, nine weeks and 6 months following intervention | |
Secondary | Change in functional exercise capacity assessed by 6-minute walk distance | Distance in meters achieved on a 6-minute walk test | Baseline, nine weeks and 6 months following intervention | |
Secondary | Changes in skeletal muscle size | Change in cross-sectional area of the Quadriceps will be measured by B-mode ultrasonography | Baseline, nine weeks and 6 months following intervention | |
Secondary | Dyspnea related disability - measured with modified medical research council scale (MMRC) | The MMRC rates dyspnea according to different levels activity on a 5-point scale (grade 0-4), with grade 4 representing the greatest level of dyspnea impairment. | Baseline, nine weeks and 6 months following intervention | |
Secondary | Global rating of change | The global rating of change will assess the participants' overall self-perceived change in health by asking the participant to rate their change as either 'worse', 'about the same' or 'better'. The extent of change ( (i.e., worsening or improvement) is then graded on a Likert scale from one to seven. | Baseline, nine weeks and 6 months following intervention | |
Secondary | Change in physical activity | Time spent sedentary and in physical activity of various intensities will be measured by a wrist-worn, tri-axial accelerometer. | Baseline, nine weeks and 6 months following intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06053164 -
Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease
|
Phase 2 | |
Recruiting |
NCT03737409 -
PFOX: Pulmonary Fibrosis Ambulatory Oxygen Trial
|
N/A | |
Recruiting |
NCT05130034 -
Home-based Pulmonary Rehabilitation and Health Coaching in Fibrotic Interstitial Lung Disease
|
N/A | |
Terminated |
NCT00415272 -
Pulmonary Rehabilitation in Patients With Fibrotic Interstitial Lung Disease
|
N/A |